Global Human Papilloma Virus (HPV) Vaccine Market - Industry Trends, Opportunities and Forecasts to 2023
DESCRIPTION The global Human Papilloma Virus (HPV) Vaccine market is expected to grow at a CAGR of XX.XX% during the forecast period to reach a total market size of US$XX.XX billion by 2023, increasing from US$XX.XX billion in 2018. Human Papilloma Virus (HPV) Vaccine protects from certain types of Human Papilloma Viruses. According to the WHO guidelines, routine vaccination is recommended to all countries along with other vaccinations. These vaccines are on the “World Health Organisation’s list of Essential Medicines” and are considered as safe and effective medicines. HPV vaccine is used for the prevention of cervical cancer, genital warts, anal cancer, vaginal cancer, vulvar cancer and mouth cancer. Food and Drug Administration (FDA) has approved Gardasil®, Gardasil® 9 and Cervarix Vaccines for providing protection against new HPV infections. Cervarix is only used in females from 9 to 25 years of age, whereas Gardasil is used by males as well. Mode of administration is through injection only. Major market players in HPV Vaccine industry include Merck & Co Inc., GlaxoSmithKline (GSK), YST Biotech Co. Ltd., Takeda Pharmaceutical Company and EyeGene Inc. By Type On the basis of type, the segmentation of the HPV vaccine market includes Quadrivalent HPV Vaccines and Bivalent HPV Vaccines. GSK in its clinical trials have proved bivalent HPV Vaccines superior over quadrivalent HPV Vaccines. By Type of Cancer Prevention On the basis of cancer prevention, the global HPV vaccine market is segmented as cervical cancer, anal cancer, vaginal cancer, vulvar cancer, mouth cancer and genital warts.
Global Human Papilloma Virus (HPV) Vaccine Market - Industry Trends, Opportunities and Forecasts to 2023
By Gender By gender, global HPV vaccines market is segmented as girls and boys. According to the WHO routine vaccination norms, vaccination of girls around 9 to 13 years of age is typically recommended. By Age Group 1. Initiation age: 9 through 12 years 2. Females: 13 through 26 years 3. Males: 13 through 21 years By Geography Market segmentation by geography is as follows: 1. North America 2. South America 3. Europe 4. Middle East 5. Africa 6. Asia Pacific 7. Rest other Countries (ROC) HPV Vaccines are approved for males in countries like United States, SAR of China, United Kingdom, South Korea, Australia and New Zealand. FDA has licensed Gardasil in US for male population.
Global Human Papilloma Virus (HPV) Vaccine Market - Industry Trends, Opportunities and Forecasts to 2023
TABLE OF CONTENTS 1. Introduction 1.1. Market Definition 1.2. Scope of the Study 1.3. Currency 1.4. Assumptions 1.5. Base, and Forecast Years Timeline 2. Research Methodology 2.1. Research Design 2.2. Secondary Sources 2.3. Validation 3. Key Findings of the Study 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunities and Market Trends 4.4. Market Segmentation 4.5. Porter’s Five Forces Analysis 4.5.1. Bargaining Power of Suppliers 4.5.2. Bargaining Power of Buyers 4.5.3. Threat of New Entrants 4.5.4. Threat of Substitutes 4.5.5. Competitive Rivalry in the Industry 4.6. Industry Value Chain Analysis 4.7. Industry Regulations 5. Global Human Papilloma Virus (HPV) Vaccine Market Forecast by Type (US$ Billion) 5.1. Introduction 5.2. Quadrivalent HPV Vaccine 5.3. Bivalent HPV Vaccine
Global Human Papilloma Virus (HPV) Vaccine Market - Industry Trends, Opportunities and Forecasts to 2023
6. Global Human Papilloma Virus (HPV) Vaccine Market Forecast by Type of Cancer Prevention (US$ Billion) 6.1. Introduction 6.2. Cervical Cancer 6.3. Anal Cancer 6.4. Vaginal Cancer 6.5. Vulvar Cancer 6.6. Mouth Cancer 6.7. Genital Warts 7. Global Human Papilloma Virus (HPV) Vaccine Market Forecast by Gender (US$ Billion) 7.1. Introduction 7.2. Girls 7.3. Boys 8. Global Human Papilloma Virus (HPV) Vaccine Market Forecast by Age Group (US$ Billion) 8.1. Introduction 8.2. Initiation 9 to 12 8.3. Females 13 through 26 8.4. Males 13 through 21 9. Global Human Papilloma Virus (HPV) Vaccine Market Forecast by Geography (US$ Billion) 9.1. Introduction 9.2. North America 9.3. South America 9.4. Europe 9.5. Middle East and Africa (MEA) 9.6. Asia Pacific (APAC) 9.7. ROC (Rest other Countries) 10. Competitive Intelligence 10.1. Market Share Analysis 10.2. Strategies of Key Players 10.3. Recent Investments and Deals Global Human Papilloma Virus (HPV) Vaccine Market - Industry Trends, Opportunities and Forecasts to 2023
11. Company Profiles 11.1. Merck & Co Inc. 11.1.1. Overview 11.1.2. Financials 11.1.3. Products and Services 11.1.4. Key Developments 11.2. GSK 11.2.1. Overview 11.2.2. Financials 11.2.3. Products and Services 11.2.4. Key Developments 11.3. YST Biotech Co. Ltd. 11.3.1. Overview 11.3.2. Financials 11.3.3. Products and Services 11.3.4. Key Developments 11.4. Takeda Pharmaceutical Company 11.4.1. Overview 11.4.2. Financials 11.4.3. Products and Services 11.4.4. Key Developments 11.5. EyeGene Inc. 11.5.1. Overview 11.5.2. Financials 11.5.3. Products and Services 11.5.4. Key Developments List of Tables List of Figures
Global Human Papilloma Virus (HPV) Vaccine Market - Industry Trends, Opportunities and Forecasts to 2023
TO ORDER OR REQUEST FOR A SAMPLE: Product: Global Human Papilloma Virus (HPV) Vaccine Market - Industry Trends, Opportunities and Forecasts to 2023 Link:https://www.knowledge-sourcing.com/products/global-human-papilloma-virus-hpvvaccine -market-industry-trends-opportunities-and-forecasts-to-2023 Price: US$3,600 – Single User License US$4,600 – Multi User License US$6,600 – Enterprise License Payment: To pay by Credit Card, please, click “Add to Cart” button on product page and proceed with the payment For wire transfer, write to us at sales@knowledge-sourcing.com
For any custom requirements or queries, please visit our website or call us: Website: www.knowledge-sourcing.com Phone: +1-866-714-4587
Global Human Papilloma Virus (HPV) Vaccine Market - Industry Trends, Opportunities and Forecasts to 2023